The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...

Race Oncology (ASX:RAC) has started working with George Clinical under a work order (WO) agreement for its Phase 1 RAC-010 ...

VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025 ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

HYDERABAD: Even with the advantage of a high population, experts said India has failed to leverage its advantage to become a ...

Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of ...